title: Thiolated chitosan-modified PLA-PCL-TPGS nanoparticles for oral chemotherapy of lung cancer.
abstract: Oral chemotherapy is a key step towards 'chemotherapy at home', a dream of cancer patients, which will radically change the clinical practice of chemotherapy and greatly improve the quality of life of the patients. In this research, three types of nanoparticle formulation from commercial PCL and self-synthesized d-α-tocopheryl polyethylene glycol 1000 succinate (PLA-PCL-TPGS) random copolymer were prepared in this research for oral delivery of antitumor agents, including thiolated chitosan-modified PCL nanoparticles, unmodified PLA-PCL-TPGS nanoparticles, and thiolated chitosan-modified PLA-PCL-TPGS nanoparticles. Firstly, the PLA-PCL-TPGS random copolymer was synthesized and characterized. Thiolated chitosan greatly increases its mucoadhesiveness and permeation properties, thus increasing the chances of nanoparticle uptake by the gastrointestinal mucosa and improving drug absorption. The PLA-PCL-TPGS nanoparticles were found by FESEM that they are of spherical shape and around 200 nm in diameter. The surface charge of PLA-PCL-TPGS nanoparticles was reversed from anionic to cationic after thiolated chitosan modification. The thiolated chitosan-modified PLA-PCL-TPGS nanoparticles have significantly higher level of the cell uptake than that of thiolated chitosan-modified PLGA nanoparticles and unmodified PLA-PCL-TPGS nanoparticles. In vitro cell viability studies showed advantages of the thiolated chitosan-modified PLA-PCL-TPGS nanoparticles over Taxol® in terms of cytotoxicity against A549 cells. It seems that the mucoadhesive nanoparticles can increase paclitaxel transport by opening tight junctions and bypassing the efflux pump of P-glycoprotein. In conclusion, PLA-PCL-TPGS nanoparticles modified by thiolated chitosan could enhance the cellular uptake and cytotoxicity, which revealed a potential application for oral chemotherapy of lung cancer.
authors: Tianjin Key Laboratory of Biomaterial Research, Institute of Biomedical Engineering, Peking Union Medical College & Chinese Academy of Medical Sciences, Tianjin, 300192, China. bmezqq@163.com.
authors: Liqin
authors: L
authors: Jiang
authors: Xuemin
authors: X
authors: Li
authors: Lingrong
authors: L
authors: Liu
authors: Qiqing
authors: Q
authors: Zhang
references: Int J Nanomedicine. 2011 Jan 12;6:119-28
references: 21289989
references: Drug Discov Today Technol. 2005 Spring;2(1):75-81
references: 24981758
references: Adv Drug Deliv Rev. 2001 Oct 1;50 Suppl 1:S69-89
references: 11576696
references: Pharm Res. 2006 Jan;23(1):184-95
references: 16267632
references: Expert Opin Pharmacother. 2000 Jan;1(2):187-206
references: 11249542
references: Acc Chem Res. 2007 May;40(5):335-42
references: 17474708
references: J Pharm Sci. 1970 Feb;59(2):154-63
references: 5411337
references: Nanomedicine. 2010 Feb;6(1):170-8
references: 19447200
references: Int J Pharm. 2005 Sep 14;301(1-2):268-76
references: 16023808
references: Mol Pharmacol. 2007 May;71(5):1185-99
references: 17220355
references: J Clin Oncol. 2001 Feb 15;19(4):1160-6
references: 11181682
references: J Control Release. 2006 Nov;116(1):1-27
references: 17050027
references: Clin Cancer Res. 2008 Mar 15;14(6):1633-8
references: 18347164
references: Adv Drug Deliv Rev. 1998 Dec 1;34(2-3):339-350
references: 10837685
references: Biomaterials. 2009 Jul;30(19):3297-306
references: 19299012
references: Int J Cancer. 2008 Aug 15;123(4):739-52
references: 18512238
references: Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):2031-5
references: 9050899
references: Int J Pharm. 2002 Dec 5;249(1-2):139-47
references: 12433442
references: J Control Release. 2005 Sep 20;107(1):43-52
references: 16081183
references: Nanoscale Res Lett. 2010 May 06;5(7):1161-9
references: 20596457
references: Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):27-43
references: 11259831
references: Int J Pharm. 2003 Jul 24;260(2):229-37
references: 12842342
references: Cancer Chemother Pharmacol. 2005 Jan;55(1):72-8
references: 15316750
references: Pharm Res. 2009 Nov;26(11):2495-503
references: 19756974
references: J Control Release. 2002 Jun 17;81(3):347-54
references: 12044573
references: J Control Release. 1998 Jul 31;54(2):201-11
references: 9724907
references: J Control Release. 2004 Nov 5;100(1):5-28
references: 15491807
references: Pharmacogenetics. 1998 Oct;8(5):391-401
references: 9825831
references: Jpn J Cancer Res. 2001 Apr;92(4):459-66
references: 11346469
references: Pharm Res. 1999 Dec;16(12):1812-7
references: 10644067
references: Int J Nanomedicine. 2012;7:1851-63
references: 22605934
references: Nanoscale Res Lett. 2011 Dec;6(1):4
references: 27502629
references: Cancer Res. 1996 Mar 15;56(6):1296-302
references: 8640817
references: Biochem Pharmacol. 1994 Oct 7;48(7):1528-30
references: 7945455
references: Adv Drug Deliv Rev. 1998 Dec 1;34(2-3):135-154
references: 10837675
references: J Nanosci Nanotechnol. 2009 Aug;9(8):4593-603
references: 19928123
references: Cancer Res. 2004 Oct 15;64(20):7426-31
references: 15492266
references: Nanoscale Res Lett. 2009 Sep 16;4(12):1530-9
references: 20652101
references: Pharm Res. 2007 May;24(5):955-62
references: 17372684
references: Acta Biomater. 2010 Jun;6(6):2045-52
references: 19969111
references: Pharm Res. 1999 Oct;16(10):1550-6
references: 10554096